Panitumumab

立即咨询

Panitumumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

339177-26-3

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

ABX-EGF

产品介绍

Panitumumab (ABX-EGF) 是一种全人源 IgG2 抗EGFR单克隆抗体，具有抗肿瘤活性。Panitumumab 抑制肿瘤细胞增殖、存活和血管生成。Panitumumab 可用于癌症研究，例如结肠癌。

生物活性

Panitumumab (ABX-EGF) is a fully humanIgG2anti-EGFRmonoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as coloncancer^[1]^[2]^[4].

体外研究
(In Vitro)

Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells^[3].
Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells^[4].
Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells^[4].

Western Blot Analysis^[3]

Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:	2, 20, 200, 2000 nM
Incubation Time:	3 h
Result:	Inhibited ligand-induced autophosphorylation of EGFR.

体内研究
(In Vivo)

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P< 0.0003)^[1].

Animal Model:	NCI-H1975 and NCI-H1650 xenografts^[3]
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

Clinical Trial

性状

Liquid

CAS 号

339177-26-3

中文名称

帕尼单抗

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.